Month: March 2023

AT A GLANCE… Copycat, compounded drugs for weight loss – multiple stories here, here and here. Altimmune presents an interim analysis this week on 160 subjects in the MOMENTUM Phase 2 Obesity Trial. Higher plasma caffeine concentrations were associated with lower body mass index and fat mass, as well as a lower risk of type 2 diabetes. EVENTS Not a ton of excitement this week, but I will

AT A GLANCE… The Oscar ceremony mocks Ozempic takers in Hollywood; Brendan Fraser wins best actor for his portrayal of a 600-lb gay man in The Whale. The Guardian, a British daily newspaper, reports on Novo Nordisk and its ‘orchestrated PR campaign’ to achieve regulatory approval Researchers calculate Medicare Part D would be on the hook for $27B, or 20% of its total budget, to serve adults 60 years

AT A GLANCE… WeightWatchers enters definitive agreement to acquire Sequence, a telehealth weight management program, with a focus upon GLP-1 medications; closely followed by Noom Clinical, a new offering to meet demand for weight loss medications. The UK National Health Service approved Novo Nordisk drug Wegovy for weight loss, though at higher BMI entry criteria of 35, and for a maximum two-year period. Cardiovascular risk factors

Dear Friends, a ton of activity on metabolic and obesity care, with Obesity Care Week, publication of report from the World Obesity Forum, all in advance of World Obesity Day on March 4. AT A GLANCE… Publication of the World Obesity Atlas estimates a $4.32 trillion cost to the global economy, or 3% of global GDP by 2035, with 4 billion people [or